{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-26-006915","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.065696+00:00","generated_at":"2026-05-15T08:48:38.172738+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tonix doses first participant in Phase 1 study of TNX-1900 for migraine and craniofacial pain","bullets":["First participant dosed in Phase 1 investigator-initiated study of TNX-1900 (intranasal potentiated oxytocin).","Study evaluates effect on trigeminal nerve-mediated vasodilation using capsaicin and electrical stimulation in healthy female volunteers.","Principal investigator Dr. Antoinette Maassen van den Brink, Erasmus University Medical Center.","TNX-1900 targets a distinct pathway from CGRP inhibitors and triptans, blocking CGRP release in animal models.","Use of Laser Speckle Contrast Imaging (LSCI) for real-time dermal blood flow measurements."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-006915","json":"https://secwatch.observer/filing/0001999371-26-006915.json","markdown":"https://secwatch.observer/filing/0001999371-26-006915.md","text":"https://secwatch.observer/filing/0001999371-26-006915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126006915/0001999371-26-006915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126006915/tnxp-8k_032526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:48:38.172738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}